Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that FOLFOX6 chemotherapy significantly decreased serum VEGF and CRP levels in advanced colorectal cancer patients, improved their quality of life as measured by KPS scores, and demonstrated a high overall therapeutic efficacy of 82.72% with manageable side effects.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

This study found that vinblastine's metabolites show binding affinities for receptors linked to nausea and alopecia, suggesting potential changes to its structure could minimize these side effects during chemotherapy.

In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.

This article discusses the ethical concerns and implications of a partnership between the National Prostate Cancer Coalition and Viadur, including the perceived endorsement of a specific drug.

This study found that securinine and ajmaline significantly inhibited hepatocellular carcinoma cell viability and induced apoptosis, with securinine showing lower toxicity to normal liver cells.

This study found that the serine protease inhibitor ONO-3403 significantly suppressed tumor growth in mice with induced squamous cell carcinoma without apparent side effects, suggesting its potential for cancer treatment.

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

The document corrects errors in previous articles, including a reversed term, updated subject weights, hair count data, and reference numbering.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

In this retrospective study conducted at Nishtar Hospital, nab-paclitaxel combined with radiotherapy provided similar survival outcomes to cisplatin in treating early-stage cervical cancer, with lower hematologic and gastrointestinal toxicity, though alopecia was more common.

In this study, induction nab-paclitaxel plus cisplatin, combined with nimotuzumab and IMRT, followed by S-1 adjuvant chemotherapy, showed excellent survival benefits with tolerable toxicities for stage N3 nasopharyngeal carcinoma patients.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.

In this study, EC chemotherapy was found to be noninferior to TC in causing grade 3 or 4 neutropenia among HR+/HER2-negative breast cancer patients, but EC was associated with more other adverse events.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.

In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.

In this study, combining deferasirox with sorafenib significantly reduced liver fibrosis and preneoplastic lesions in rats while also lessening adverse effects compared to sorafenib alone.

Endoxan often causes hair loss, which usually starts in the third week of treatment.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

This study found that minoxidil and ranolazine, individually and in combination, reduced cellular invasiveness in hypoxic triple-negative breast cancer cell lines, suggesting potential anti-metastatic effects at clinically relevant doses.

This review highlights GA-mediated nanoparticles for liver-targeting drug delivery in liver cancer treatment and reports no new clinical results.